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ABSTRACT 
Both morphological and molecular approaches have highlighted the biological and prognostic 
importance of the tumour microenvironment in colorectal cancer (CRC). Despite this, 
microscopic assessment of tumour microenvironment has not been adopted into routine 
practice. Based on existing evidence, we selected specific morphological features relating to 
peritumoral inflammatory and stromal responses, agreed criteria for scoring, and assessed 
these in representative H&E-stained whole tumour sections, from a population-based cohort 
of 445 stage II/III colon cancer cases. Moderate/severe peritumoral diffuse lymphoid 
inflammation and Crohn’s disease-like reaction were associated with significantly reduced 
risks of CRC-specific death (adjusted HR 0.48, 95% CI 0.31-0.76, and HR 0.60, 95% CI 
0.42-0.84, respectively).  The presence of >50% tumour stromal percentage, assessed by 
global evaluation of tumour area, was associated with a significantly increased risk of CRC-
specific death (HR 1.60 95% CI 1.06-2.41).  A composite, “fibroinflammatory score” (0-3), 
combining dichotomised scores of these three features, showed a highly significant 
association in relation to survival outcomes. Those with a score ≥2 had an almost 2.5 fold 
increased risk of CRC-specific death (HR 2.44, 95% CI: 1.56-3.81), compared with those 
scoring zero. These associations were stronger in MSI-high tumours, potentially identifying a 
subset of MSI-high colon cancers which lack characteristic morphological features and have 
an associated worse prognosis. In summary, reporting on H&E staining of selected 
microscopic features of the tumour microenvironment, independently or in combination, 
offers valuable prognostic information in stage II/III colon cancer and may allow 
morphological correlation with developing molecular classifications of prognostic and 
predictive relevance.  
KEYWORDS: colorectal cancer; stroma; inflammation; prognosis; survival. 
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INTRODUCTION 
Colorectal cancer (CRC) is a leading cause of cancer death in developed countries, and is 
estimated to increase in incidence worldwide, particularly in low-middle income countries. 
(1,2) Evaluation of tumour morphology has been the mainstay of prognostication for decades, 
guiding management through assessment of tumour grade, stage and other histological 
features of proven clinical significance. Recently there has been a major focus on 
transcription-based molecular classification of CRC and prognostic significance of subtypes. 
(3-5) However, given the limited availability and current high cost for routine molecular 
subtyping of CRC, this is likely to remain a future goal for the present time. 
Both morphological studies and recent molecular classifications of CRC have highlighted the 
importance of the tumour microenvironment, reinvigorating interest in the “seed and soil” 
hypothesis of colorectal carcinogenesis. (6) The first CRC consensus molecular subtype 
(CMS) classification, which combined gene expression data from over 4000 patients, 
includes “immune” (CMS1) and “mesenchymal” (CMS4) subtypes. (5) The defining 
contribution of the tumour microenvironment to the overall expression profile traits 
associated with each subtype has since been highlighted, in addition to the potential for 
misclassification due to intratumoral heterogeneity in localised regions of the primary 
tumour. (7-9) Many prior morphological studies, some decades old, have examined selected 
features of the tumour microenvironment. Previous assessments by routine microscopy of 
haematoxylin and eosin (H&E)-stained sections demonstrated prognostic significance of a 
variety of features related mainly to peritumoral inflammation and stromal reaction. (10-28) 
However, there has been limited validation of results in larger studies. Lack of 
standardisation of methods of assessment and unconvincing interobserver reproducibility for 
some parameters has prevented uptake into routine reporting practice. 
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There is an ongoing need for more reliable and reproducible prognostic morphological 
features in CRC, especially in stage II disease given well documented divergent clinical 
outcomes. (29-31) In addition, there is a desire to maximise all available information from 
routine pathological assessment of CRC resection specimens. To this end, we have chosen 
from existing literature the most promising tumour microenvironmental features, related to 
host immune and stromal proliferative responses. We have evaluated these on H&E-stained 
whole tumour sections derived from a large population-based cohort of stage II and stage III 
colon cancer cases. Interobserver and intraobserver reproducibility was rigorously assessed. 
The overall study aim was to identify those tumour microenvironmental features most likely 
to provide prognostic information and be feasible to use in routine pathology reporting 
practice. 
  
5 
 
MATERIALS AND METHODS 
Case Identification 
Stage II and III colon cancer patients (ICD-code C.18, n=1,862) diagnosed in Northern 
Ireland from 2004 and up to 2008 were identified from the Northern Ireland Cancer Registry.  
Rectal and rectosigmoid junction cancers were excluded due to the potential for neoadjuvant 
therapy to alter tumour morphology. Exclusions were applied to retain only patients with a 
single, primary colon adenocarcinoma, which had been treated by surgical resection 
(n=1,539). A detailed clinical case note review was conducted, to verify diagnosis and stage 
and to extract clinical information including the use of adjuvant chemotherapy and outcome. 
Following this review, n=113 cases were excluded, mainly on the basis of inaccurate staging.  
Of the remaining n=1,426 patients, n=740 patients (52%) were diagnosed within the 
jurisdiction of the Northern Ireland Biobank, allowing retrieval of glass slides for pathology 
review. Slides from n=661 (89%) of these cases were located and, within the study 
timeframe, n=473 consecutive cases underwent slide review and evaluation in this study. 
These cases were representative of the overall n=661 cases with available slides, except they 
were more likely to be diagnosed in earlier years of the cohort due to the consecutive nature 
of slide review (data not shown). All patients were followed up for occurrence and cause of 
death via linkage to the Northern Ireland Registrar General’s Office up to 31st December 
2013.  Patients were recorded as having a CRC specific death if any cause of death was listed 
as ICD-codes C18, C19, C20 and/or C26. Ethical approval for resection specimen retrieval 
was received from the Northern Ireland Biobank (REC:11/NI/0013, project NIB13-0069). 
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Morphology Review Process 
Generation of the NIB13-0069 study resource included review of all glass slides from the 
relevant surgical resection specimens to select the two most representative tumour blocks 
from each case, at least one of which represented the advancing edge/invasive margin of the 
tumour.  Slide review for this study was based on further evaluation of these two 
representative H&E-stained slides for each case. All cases were reviewed for the selected 
morphological features by a pathology fellow with an interest in gastrointestinal pathology 
(SOH). Prior to the study review, random colonic adenocarcinoma cases (n=10) were 
discussed at two multi-header microscopy conference sessions with three other pathologists, 
two consultant gastrointestinal pathologists (MBL and PJK) and one trainee pathologist (SI). 
These four comprised the study pathologist group. The purpose of these sessions was firstly 
to select suitable morphological features of potential relevance to the study, based on existing 
evidence, and secondly to decide what criteria to apply to define and score these parameters, 
applicable to routine practice.  
After agreement on study parameters and criteria for scoring, a random set of 36 cases 
(representing 5% of the overall 661 cases eligible for inclusion in the study) was chosen for 
blinded interobserver and intraobserver analysis, the latter following a six week washout 
period. These analyses involved all observers evaluating both available slides for each case, 
without any annotations or other indicators of the regions of interest chosen by others. 
In addition to the chosen microenvironmental features, the study also assessed tumour 
typing/subtyping and differentiation, based on World Health Organisation 2010 criteria.  (32) 
Other pathology data items, including nodal status and presence or absence of extramural 
venous invasion, were recorded from pathology reports. The agreed approach and scoring 
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system applied to the study microenvironmental features evaluated is described below and 
summarised in Table 1.  
 
Peritumoral Lymphoid Inflammation 
The Klintrup–Makinen system, based on H&E assessment of overall inflammatory response 
(all inflammatory cell types) at the advancing tumour edge, is widely validated and 
considered to be reproducible and more valuable than the simpler, preceding Jass scoring 
system. (10,13,17,21) However, available evidence suggests that, within the inflammatory 
infiltrates, it is the lymphoid population, assessed on routine microscopy or on 
immunohistochemistry, which is of most prognostic value. (12,13,15,17,24) Some studies 
have indicated that immunohistochemical evaluation of specific subsets of lymphoid cell 
populations currently adds little prognostic value over H&E assessment. (12,13,15,33) A 
modification of the Klintrop-Makinen scoring system was therefore chosen, assessing 
lymphoid cell infiltrates only, within stromal tissue along the invasive tumour front, and 
ignoring other inflammatory cell populations. Lymphoid infiltrates were scored as 
absent/mild, featuring scattered lymphocytes only (0); moderate, with a band-like mantle 
infiltrate and at least focal gland destruction (1); and severe, demonstrating a cup-like 
lymphoid reaction and marked gland destruction (2). This scoring is illustrated in Figure 1. 
 
Crohn’s Disease-like Reaction 
In addition to peritumoral lymphoid reaction at the advancing edge, the so-called Crohn’s 
disease-like reaction (CLR) in peritumoral tissue was also assessed. In contrast to peritumoral 
diffuse lymphoid inflammation, Crohn’s disease-like lymphoid aggregates are comprised 
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predominantly of B-cells rather than T-cells. (12) These organised lymphoid structures are an 
essential component of adaptive immunity. (34) Compared to peritumoral T-cell reaction, 
relatively little evidence exists for the prognostic value of CLR in CRC. (12,23,35) Scoring 
was based on the Graham and Appelman criteria, with three categories: none or a maximum 
of one peritumoral lymphoid aggregate per section (0); occasional lymphoid aggregates with 
no or rare germinal centres (1); and numerous lymphoid aggregates, some with germinal 
centres (2). (23) This scoring is illustrated in Figure 2. 
 
Tumour Stromal Percentage 
Multiple studies have reported intratumoral stroma:epithelium ratio or tumour stromal 
percentage to be prognostic in stage I-III CRC, assessed by different methodologies. 
(11,20,22,26) Mesker et al simply applied a visual estimation of percentage epithelium and 
stroma on the whole available tumour area. (20) Two more recent studies employed a focal 
assessment within a single low-power field from the advancing tumour edge. (22,26) Both of 
these methods were applied in this study. The global assessment categorised tumours as 
>50% or <50% tumour stromal percentage. The focal method involved choosing the most 
invasive region of the tumour at scanning magnification then, at x10 objective, selecting a 
field from this region in which tumour epithelium was present at the four cardinal points of 
the field. A visual estimate of tumour stromal percentage by area was then made from within 
this single x10 field, categorised as <50% or >50%. In both the global and focal assessments, 
empty glandular luminal space, luminal necrosis, extracellular mucin and native smooth 
muscle tissue were excluded in the visual assessment of tumour stromal percentage. 
Examples of tumours with high and low stromal percentages are shown in Figure 3. 
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Microsatellite Instability Analysis 
DNA was extracted according to the manufacturer’s instructions from five 5μm sections of 
representative tumour blocks using the Maxwell 16 Instrument (Promega, Southampton, UK) 
and Promega DNA extraction kit, after enrichment for tumour by slide annotation and macro-
dissection. Quantification of DNA was performed by an absorbance method using the 
NanoDrop 2000c spectrophotometer (Thermo Scientific, Wilmington, USA).  Microsatellite 
instability (MSI) analysis was performed within the Northern Ireland Molecular Pathology 
Laboratory according to manufacturer’s instructions using the MSI Analysis System, version 
1.2 kit (Promega, Southampton, UK) for five mononucleotide repeat markers (BAT-25, 
BAT-26, NR-21, NR-24 and MONO-27).  PCR products were separated by capillary 
electrophoresis using an ABI 3500 Genetic Analyzer (Fisher Scientific – UK Ltd, 
Loughborough, UK). The output data was analysed using GeneMapper® v4.1 (Fisher 
Scientific – UK Ltd, Loughborough, UK) to determine MSI-high (MSI-H) status versus non 
MSI-H (MSI-low or stable).  
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Statistical Analysis 
Of the n=473 cases reviewed in this study, patients with a known familial CRC predisposition 
syndrome (n=5) or who died within the first 30 days of follow-up (n=23) were excluded, 
leaving n=445 colon cancer patients in our analytical dataset. Kappa values were generated to 
compare interobserver and intraobserver variability in scoring morphological features. 
Fleiss’s cutoffs indicate poor, fair to good and excellent agreement for kappa scores of <0.4, 
0.4-0.75, and >0.75, respectively. 
Cox proportional hazards analysis was applied to generate hazard ratios (HR) and 
corresponding 95% confidence intervals (95% CI) for overall and CRC-specific survival 
according to morphological features. Patients were followed up from their date of diagnosis 
as per cancer registry records until their date of death or 31st December 2013.  Survival 
analysis was conducted both prior to and after adjustment for potential confounders age, sex, 
family history of CRC, ECOG performance status, tumour stage, tumour grade, extramural 
venous invasion and MSI status.  Morphological tumour subtype was tested as a confounder 
but did not alter results, and therefore was not included in the final model.  Overall survival 
analysis was also adjusted for Charlson co-morbidity score. 
All morphological features were then entered into a regression model and any that had a 
p<0.25 were considered to be associated with CRC-specific death – this group comprised 
peritumoral lymphoid inflammation, CLR and global tumour stromal percentage assessment. 
Each of these features were then dichotomised so that individuals were assigned a score of 0 
or 1 for each whereby 1 = absent/mild peritumoral lymphoid inflammation, absent/mild CLR 
and >50% global tumour stromal percentage (on the basis that these factors were associated 
with poorer outcomes on individual analysis). Patients could therefore have a combined 
morphological fibroinflammatory score range of 0-3 (Table 1).   
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Stratified analysis for individual morphological features, and combined score, was conducted 
according to MSI status, chemotherapy receipt and tumour stage. Likelihood ratio tests were 
applied to formally assess the interaction between these features and CRC survival. All 
statistical analysis was conducted using Stata version 11.2 (StataCorp, College Station, TX, 
USA).   
 
 
12 
 
RESULTS 
Characteristics of colorectal cancer patients and tumours 
As shown in Table 2, over a mean 5.5 years (range 0.1-10 years) of follow-up, 206 colon 
cancer patients had died, of which n=144 died from a CRC-specific cause.  Patients who died 
from CRC were more likely to be older, have higher ECOG scores (reflecting overall poorer 
health) and were less likely to receive adjuvant chemotherapy than patients still alive at the 
end of follow-up.  No differences in sex distribution or family history of CRC were observed. 
In terms of tumour biology, patients who died from CRC were more likely to have higher 
stage disease, nodal involvement and presence of extramural venous invasion, and less likely 
to have MSI-high tumours, compared with patients who survived, whereas no differences 
were seen by WHO tumour type. Similar differences were noted for all-cause deaths. 
Interobserver and intraobserver variation for scoring morphological features 
Assessment of CLR and tumour stromal percentage by global method demonstrated 
acceptable levels of interobserver and intraobserver variability (Table 3).  Peritumoral 
lymphoid inflammation demonstrated excellent intraobserver agreement but only poor-fair 
interobserver agreement. Interobserver and intraobserver agreement on assessment of tumour 
stromal percentage by focal method was only good at best.  
Microenvironmental morphological features and survival 
The two measures of inflammation assessed have some overlap, in that they both looked at 
peri-tumoural lymphoid reactions.  Within the overall patient cohort (of n=445), 277 (62.2%) 
were scored as 1 or 2 for both peri-tumoural lymphoid inflammation and CLR, while 38 
(8.5%) were scored as 0 for both.  Approximately one quarter of patients (n=115, 25.8%) 
scored 1 or 2 for peritumoral lymphoid inflammation but 0 for CLR, while 15 (3.4%) scored 
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1 or 2 for CLR but 0 for peritumoral lymphoid inflammation. These proportions were similar 
regardless of MSI status (data not shown).  
As shown in Table 4, the presence of moderate/severe peritumoral diffuse lymphoid 
inflammation and/or CLR was associated with significant 40-52% reduced risks of CRC 
death (adjusted HR 0.48, 95% CI 0.31-0.76, and HR 0.60, 95% CI 0.42-0.84, respectively).  
These associations maintained significance, but were attenuated to 36-37% reduced risks of 
death from any cause, suggesting that this good prognostic influence is driven by a CRC-
specific effect.  
The presence of >50% tumour stromal percentage, assessed globally, was associated with an 
increased risk of CRC death (HR 1.60 95% CI 1.06-2.41) and death from any cause (HR 
1.52, 95% CI 1.07-2.16). These results were slightly attenuated for CRC-specific survival but 
remained significant for overall survival after adjustment for other prognostic confounders 
(Table 4). Tumour stromal percentage assessed focally was not associated with survival 
outcomes in this cohort. 
Combined morphological ‘fibroinflammatory’ score and survival 
The composite score based on dichotomised scores of three features (peritumoral lymphoid 
inflammation, CLR and tumour stromal percentage) revealed a highly significant association 
when analysing this score in relation to survival outcomes, even after adjustment for known 
confounders including differentiation (Table 5, Figure 4).  Patients with a score of one had a 
53% increase in the hazard for CRC-specific death (HR 1.53, 95% CI: 1.02-2.28), and those 
with a score ≥2 had an almost 2.5 fold increased risk of CRC-specific death (HR 2.44, 95% 
CI: 1.56-3.81), compared with those scoring zero. Similar results were seen for all cause 
mortality. 
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Sub-group analysis by MSI status, chemotherapy use, and tumour stage 
Figure 5 illustrates similar directions of prognostic influence of the morphological features in 
both MSI status groups, although the magnitude of associations was considerably stronger in 
the MSI-high group.  Patients with a fibroinflammatory score of 2 or 3, in comparison with 
those having a score of 0, had a 66% increased risk of CRC-death in the non MSI-high group, 
compared to a six-fold increased risk of CRC-death in the MSI-high group, although the 
latter is based on a very small number of patients (n=8 patients had MSI-H tumours with a 
fibroinflammatory score of 2 or 3, and seven of these patients died during the follow-up 
period).  A significant interaction was observed between CRC survival, MSI status and 
peritumoral inflammatory infiltrate (p=0.002), and the overall fibroinflammatory score 
(p=0.01).   
Subgroup analysis by adjuvant chemotherapy receipt and tumour stage revealed largely 
similar results to those seen in the overall cohort of CRC patients, although the magnitude of 
associations for inflammatory features was slightly stronger in stage III compared with stage 
II patients (Supplementary Table 1).  
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DISCUSSION 
The results from this large population-based cohort of stage II and III colon cancer patients 
indicate that three tumour microenvironmental features not currently reported in routine 
practice – peritumoral lymphoid infiltrate, CLR and global assessment of tumour stromal 
percentage - are predictive of survival outcomes.  These associations were evident when 
taking into consideration other established prognostic factors, such as tumour grade, stage, 
extramural venous invasion and MSI status, and patient demographics.  With some caveats, 
assessment of these features has acceptable interobserver and intraobserver variation, 
suggesting that their introduction into routine clinical practice is feasible.   
Despite significant progress in the molecular understanding of colorectal carcinogenesis, 
routine pathology reporting remains largely based on microscopic tumour assessment. 
Furthermore, reporting is focussed almost exclusively on the epithelial tumour component, 
for example in staging and grading, and the tumour microenvironment is largely ignored. 
(36,37) This is despite numerous morphological studies demonstrating prognostic 
significance of selected tumour microenvironmental features (10-28). Broadly, these have 
related either to peritumoral inflammatory response or to the intratumoral stromal component. 
Peritumoral inflammation in CRC has been the subject of a large number of studies, both 
morphological and immunohistochemical, and recently a proposal has been advanced to 
report an Immunoscore for all CRC cases, applying immunohistochemistry and digital image 
analysis for scoring. (24) The presence of a significant peritumoral inflammatory infiltrate 
has assumed increased potential relevance recently for therapy-related decisions, with the 
advent of immune-based therapies including checkpoint CTLA-4, PD-1 and PDL-1 inhibitors 
such as ipilimumab which are currently being investigated in trials in colorectal and other 
cancers. (38) For example, we recently highlighted the presence of a good prognostic group 
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in stage III CRC defined by high PD-L1 gene expression within the peritumoral immune cell 
infiltrate.  (39) 
Routine application of multiple biomarkers by immunohistochemistry and digital image 
analysis for scoring remains unfeasible in routine reporting practice however, particularly 
within low-middle income countries where CRC incidence is rising most, and so more 
consideration of routine H&E assessment is required. Regarding peritumoral inflammatory 
composition, the lymphoid component appears to offer most prognostic information, beyond 
the overall peritumoral inflammatory assessment favoured by Klintrop-Makinen, or other 
selected inflammatory cell populations, and so peritumoral lymphoid inflammation was the 
chosen parameter in this study. Although interobserver variation in assessment was only 
poor-fair, post-study discussion by the four study pathologists suggested this was in part 
related to the handling of certain inflammatory sub-populations e.g. plasma cells. This 
highlights the importance of meticulous attention to standardisation of assessment criteria and 
agreement of definitions. Intraobserver variation was excellent and previous studies have also 
indicated good reproducibility for assessment of peritumoral inflammatory cell populations 
on H&E examination. (16,21) Nevertheless, reproducibility of such assessments is of 
paramount importance and requires rigorous evaluation in all such morphological studies and 
further careful consideration prior to incorporation of such assessments into routine practice. 
Whether evaluation of specific peritumoral inflammatory cell populations is preferably done 
by H&E examination or by immunohistochemistry, in addition requires consideration of 
resource and prognostic or predictive clinical application.  
Both peritumoral lymphoid inflammation and CLR demonstrated a protective prognostic 
effect in this study, and of similar magnitudes. This supports numerous previous studies of 
peritumoral diffuse inflammation, based on morphological and immunohistochemical 
assessments. (12,13,15,17,24) Less literature exists on the prognostic benefit of CLR in CRC, 
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although one study, by Graham and Appelman, dates from 1990.  (23) A recent, large study 
of CRC stages I-IV, reported prognostic value of peritumoral lymphoid aggregates that was 
independent of stage and of peritumoral inflammatory assessment (assessed by Klintrup-
Makinen score). (13)  
There was considerable overlap in scoring patterns for peritumoral lymphoid inflammation 
and CLR. Of the approximately 30% of patients in the cohort having differential scoring for 
these two inflammatory parameters, most of these discordant cases scored 1 or 2 for 
peritumoral inflammation and 0 for CLR. A smaller proportion of patients 3.4%, (n=15) 
conversely scored 1 or 2 for CLR and 0 for peritumoral lymphoid inflammation. Importantly, 
in the present study reproducibility of CLR assessments was significantly better than for 
peritumoral lymphoid inflammation. Thus we consider both worthy of independent 
assessment, in accordance with the study by Klintrup et al, which concluded that CLR and 
inflammatory reaction at the advancing tumour edge do not represent a phenotypic variation 
of the same immune defence mechanism, but rather are independent and each of prognostic 
value. (21) 
We adopted two approaches to assessing tumour stromal percentage, one global and one 
focal, both reported previously to have prognostic relevance in CRC. (20,22,26) West et al 
used a more precise morphometric method, and demonstrated similar findings, but this 
approach is considered too time-consuming for routine use, taking on average 20 minutes per 
case in that study. (11) We found the global assessment of >50% tumour stromal percentage, 
but not the focal assessment, to be associated with significantly increased hazard for a CRC-
specific cause of death. Both intraobserver and interobserver reproducibility of global stromal 
assessment was also much better than of focal stromal assessment. This contradicts findings 
from two previous studies, both describing excellent reproducibility of the focal method. 
(22,26) However, while our study allowed each pathologist to select an independent study 
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field based on their own assessment of the requirements, neither of these papers describes in 
sufficient detail how interobserver variability was assessed, specifically how independent was 
selection of study fields between observers. On post-study evaluation, we found selection of 
“the most invasive field”, required by the Huijbers et al method, varied considerably between 
study participants, even when examining only two slides per case, and this had a profound 
influence on reproducibility. This can only be expected to be a greater problem in everyday 
reporting practice, with more tumour slides to evaluate per case. Global assessment, 
considering all available tumour tissue area, as originally proposed by Mesker et al in a 
smaller study, appears to be a more reproducible and valuable parameter.(20) 
Combining dichotomised scores from the three tumour microenvironmental features found to 
be of prognostic value, a ‘fibroinflammatory score’ (0-3) was derived for each case, and was 
found to better predict prognosis than any of the individual features, with a highly significant 
association evident. One previous study has assessed similar tumour microenvironmental 
features in a large CRC cohort, and described tumour stromal prognostic influence in the 
context of local and systemic host responses, including peritumoral inflammation, but, to our 
knowledge, this is the first study to combine these features to derive a tumour 
microenvironmental score of local stromal and inflammatory response. (26) The potential for 
confounding interobserver variation in assessments of individual features can be reduced by 
using the proposed combined score. 
This proposed addition to routine morphological assessment of CRC correlates well with 
renewed interest in tumour microenvironment, and the concept of distinguishing features of 
the tumour “seed” (malignant epithelium) from tumour “soil” (immune system and stroma). 
(6) This impacts on proposed transcriptional profiling of CRC, with CMS subtypes including 
an “immune” subtype (CMS1), characterised largely by microsatellite instability and related 
clinicopathological features including excellent prognosis, and a “mesenchymal” subtype 
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(CMS4), characterised by microsatellite stability, epithelial-mesenchymal transition and poor 
prognosis. (5) Sub-analysis by MSI status in our cohort suggests that, within the group of 
MSI-H colon cancers, there exists a sub-group which lacks the characteristic morphological 
features (scoring 2 or 3 for fibroinflammatory score), and this group has a worse prognosis 
than MSI-H tumours with classical morphology. Therefore, morphological assessment of the 
tumour microenvironment adds value beyond MSI status to prognostication in the MSI-H 
group in particular. This is in agreement with our findings from a transcription-based study, 
where some MSI-H tumours appeared to have a low immune infiltration signature similar to 
non-MSI high tumours.  (39) Additionally, these findings support a recent study indicating 
that tumour Immunoscore offers greater prognostic value than assessment of MSI status. (40) 
The strengths of this study include its population-representative cohort of stage II and III 
colon cancer patients, relatively large overall study numbers, careful consideration of 
reproducibility of assessments and feasibility for introduction into routine practice and 
correlation of traditional morphological assessment with current molecular approaches to 
CRC subtyping. A study weakness is that restriction of tumour assessments to two slides per 
case, rather than examining all tumour slides, does not reflect real life practice and may 
distort somewhat data on reproducibility. Also, we have not examined rectal cancers in this 
study. 
In summary, supporting previous studies, we have found that reporting of selected features of 
the tumour microenvironment in stage II/III colon cancer, offers prognostic information. We 
consider a combination of peritumoral lymphoid inflammation at the advancing edge, 
Crohn’s disease-like reaction and tumour stromal percentage as the microenvironmental 
features likely to be most reproducibly assessed and offer the most prognostic value. We 
propose therefore that assessment of these tumour microenvironmental parameters be 
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introduced into routine reporting practice, at least until such times that adjunctive targeted 
immunohistochemistry panels and digital image analysis are more readily available.  
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FIGURES 
Figure 1. Examples of peritumoral lymphoid infiltrate scoring: score 0, absent/mild, 
featuring scattered lymphocytes only (A, x100); score 1, moderate, with a band-like mantle 
infiltrate and at least focal gland destruction (B, x100); score 2, severe, demonstrating a cup-
like lymphoid reaction and marked gland destruction (C, x100).  
Figure 2. Examples of Crohn’s disease-like reaction scoring: score 0, none or a maximum of 
one peritumoral lymphoid aggregate (A, x40); score 1, occasional lymphoid aggregates with 
no or rare germinal centres (B, x40); score 2, numerous lymphoid aggregates, some with 
germinal centres (C, x40). 
Figure 3. Examples of colon cancers with less than 50% (A, x40) and greater than (B, x40) 
tumour stromal percentage. 
Figure 4. Kaplan Meier graph showing colorectal cancer-specific survival amongst stage II 
and III colon cancer patients according to combined fibroinflammatory score. 
Figure 5. Risk of colorectal cancer-specific death according to tumour microenvironmental 
features in stage II and III colon cancer cases, stratified by microsatellite instability status.
 Table 1. Approach to scoring of histological features.  
Feature Approach to scoring Scoring categories References 
Peritumoral 
inflammation 
 
Restricted to lymphoid infiltrates only, ignoring other 
inflammatory cell populations, and assessed along the 
invasive front of the tumour. 
0 = absent/mild (scattered lymphoid cells only) 
1 = moderate, a band-like infiltrate and focal gland destruction 
2 = severe, a cup-like lymphoid reaction and marked gland 
destruction.        
 (21) 
Crohn’s disease-
like lymphoid 
reaction 
 
Assessed along the invasive front of the tumour, ignoring 
normal mucosal/submucosal lymphoid aggregates. 
0 = 0-1 peritumoral lymphoid aggregate per section 
1 = occasional lymphoid aggregates with no or rare germinal centres 
2 = numerous lymphoid aggregates, some with germinal centres  
 (23) 
Tumour stromal 
percentage (focal) 
The most invasive region of the tumour was selected at 
scanning magnification then, at 10x objective, a field was 
selected from this region in which tumour was present at the 
four cardinal points. A visual estimate of tumour stromal 
percentage by area was then made from within this single 
x10 field. Empty glandular luminal spaces, luminal necrosis, 
extracellular mucin and native smooth muscle tissue were 
excluded in this assessment. 
0=  <50% tumour stromal percentage  
1= >50% tumour stromal percentage  
 
 
 (22,26)   
 
Tumour stromal 
percentage 
(global) 
At scanning magnification, the overall tumour stromal 
percentage was estimated. Empty glandular luminal spaces, 
luminal necrosis, extracellular mucin and native smooth 
muscle tissue were excluded in this assessment. 
A visual estimate of tumour stromal percentage, expressed as the 
total area of tumour stroma plus epithelium, was categorised as: 
0=  <50% stroma  
1= >50% stroma  
  
 (20) 
Combined  
fibroinflammatory 
score 
Three of the above features, selected on the basis of those 
associated with poorest outcomes on individual analysis, 
were dichotomised so that individuals were assigned a score 
of 0 or 1 for each. Patients could therefore have a combined 
morphological fibroinflammatory score range of 0-3.  
 
Combined fibroinflammatory score, totalled from above features 
whereby: 
1 = absent/mild peritumoral lymphoid inflammation 
1 = absent/mild Crohn’s disease-like lymphoid reaction 
1 = >50% global tumour stromal percentage 
 
 
 Table 2. Descriptive characteristics of colon cancer cases by vital status at end of follow-up period.  
Characteristic Total 
n=445 (%) 
Alive  
n=239 (%) 
Death 
n=206 (%) 
CRC death 
n=144 (%) 
Sex  
  Male 
  Female 
 
237 (53.3) 
208 (46.7) 
 
126 (52.7) 
113 (47.3) 
 
111 (53.9) 
95   (46.1) 
 
82 (56.9) 
62 (43.1) 
Age, years  
  Median (IQR) 
  <50 
  50-<60 
  60-<70 
  70-<80 
  ≥80 
 
73 (65-79) 
20 (4.5) 
39 (8.8) 
121 (27.2) 
175 (39.3) 
90 (20.2) 
 
70 (63-76) 
13 (5.4) 
28 (11.7) 
79 (33.1) 
90 (37.7) 
29 (12.1) 
 
76 (69-81) 
7   (3.4) 
11 (5.3) 
42 (20.4) 
85 (41.3) 
61 (29.6) 
 
78 (74-83) 
6   (4.2) 
9   (6.3) 
37 (25.7) 
54 (37.5) 
38 (26.4) 
Year of diagnosis  
  2004 
  2005 
  2006 
  2007 
  2008 
 
95    (21.4) 
117 (26.3) 
78    (17.5) 
81    (18.2) 
74    (16.6) 
 
41 (17.2) 
59 (24.7) 
33 (13.8) 
52 (21.8) 
54 (22.6) 
 
54 (26.2) 
58 (28.2) 
45 (21.8) 
29 (14.1) 
20 (9.7) 
 
35 (24.3) 
43 (29.9) 
33 (22.9) 
17 (11.8) 
16 (11.1) 
ECOG status 
  0-1 
  2 
  3-4 
  Unknown 
 
237 (53.3) 
30   (6.7) 
17  (3.8) 
161 (36.2) 
 
138 (57.7) 
11    (4.6) 
4      (1.8) 
86   (36.0) 
 
99 (48.1) 
19 (9.2) 
13 (6.3) 
75 (36.4) 
 
65 (45.1) 
15 (10.4) 
10 (6.9) 
54 (37.5) 
Charlson co-morbidity score 
    Median (IQR) 
 
0 (0-1) 
 
0 (0-1) 
 
0 (0-1) 
 
0 (0-1) 
Family history CRC 
  No 
  Yes 
  Unknown 
 
227 (51.0) 
54    (12.1) 
164 (36.9) 
 
128 (53.6) 
33   (13.8) 
78   (32.6) 
 
99 (48.1) 
21 (10.2) 
86 (41.7) 
 
69 (47.9) 
19 (13.2) 
56 (38.9) 
Adjuvant chemotherapy use 
  No  
  Yes 
 
320 (71.9) 
125 (28.1) 
 
157 (65.7) 
82   (34.3) 
 
163 (79.1) 
43   (20.9) 
 
105 (72.9) 
39   (27.1) 
Stage  
  II 
  III 
 
275 (61.8) 
170 (38.2) 
 
160 (70.0) 
79   (33.0) 
 
115 (55.8) 
91   (44.2) 
 
65 (45.1) 
79 (54.9) 
Nodal status 
  N0 
  N1 
  N2 
 
275 (61.8) 
110 (24.7) 
60    (13.5) 
 
160 (70.0) 
54   (22.6) 
25   (10.4) 
 
115 (55.8) 
56   (27.2) 
35   (17.0) 
 
65 (45.1) 
47 (32.6) 
32 (22.2) 
Differentiation  
  Well/moderate 
  Poor 
 
408 (91.7) 
37   (8.3) 
 
223 (93.3) 
16    (6.7) 
 
185 (89.8) 
21   (10.2) 
 
129 (89.6) 
15   (10.4) 
Extramural venous invasion 
  No 
  Yes 
  Unknown 
 
293 (65.8) 
108 (24.3) 
44   (9.9) 
 
173 (72.4) 
48   (20.1) 
18   (7.5) 
 
120 (58.3) 
60   (29.1) 
26   (12.6) 
 
80 (55.6) 
50 (34.7) 
14 (9.7) 
Tumor (sub)type 
  Adenocarcinoma, NOS 
  Other* 
 
412 (92.6) 
33   (7.4) 
 
222 (92.9) 
17   (7.1) 
 
190 (92.2) 
16   (7.8) 
 
131 (91.0) 
13   (9.0) 
  
 
 
Table 2 legend. 
CRC death: Colorectal cancer-specific death; ECOG: Eastern Cooperative Oncology Group 
performance status of cancer patients' general well-being and activities of daily life, 0-1: fully active 
or restricted strenuous activity but able to carry out light activities, 2: ambulatory and able to self-
care, unable to carry out work activities, 3-4: limited or no self-care, or bedbound; NOS: not 
otherwise specified; MSI: microsatellite instability. IQR: Inter-quartile range. 
*All tumours were coded by cancer registry as adenocarcinoma. Following slide review in this study, 
specific types/subtypes identified other than adenocarcinoma, NOS, comprised mucinous 
adenocarcinoma (n=29), medullary carcinoma (n=3) and signet ring cell adenocarcinoma (n=1).   
 
 
MSI Status  
  Non MSI-high 
  MSI-high 
  Unknown 
 
309 (70.2) 
99   (22.5) 
32   (7.3) 
 
164 (69.8) 
60   (25.5) 
11   (4.7) 
 
145 (70.7) 
39   (19.0) 
21   (10.2) 
 
107 (74.8) 
22   (15.4) 
14   (9.8) 
 Table 3. Kappa values reflecting inter-observer and intra-observer variation in assessment of  
morphological features between four pathologists. 
 Pathologist 1 2 3 Judgement on variation 
Peritumoral 
inflammation 
(0 v. 1/2) 
4 0.48 0.30 0.16 Interobserver: poor-fair 
3 0.05 0.30   
2 0.44    
1* 0.79   Intraobserver: excellent 
Crohn’s disease-like 
lymphoid reaction  
(0 v. 1/2) 
4 0.84 0.58 0.46 Interobserver: poor-excellent 
3 0.47 0.29   
2 0.62    
1* 0.84   Intraobserver: excellent 
Tumor stromal 
percentage (focal) 
(<50% v. >50%) 
4 0.53 0.49 0.22 Interobserver: poor-good 
3 0.13 0.43   
2 0.21    
1* 0.45   Intraobserver: fair-good 
Tumor stromal 
percentage (global) 
(<50% v. >50%) 
4 1.00 0.55 0.48 Interobserver: good-excellent 
3 0.48 0.75   
2 0.55    
 1* 0.84   Intraobserver: excellent 
*Intra-observer variation kappa from same pathologist after a six week wash-out period.  
 
 Table 4.  Risk of colorectal cancer-specific or overall death according to morphological features in stage II and III colon cancer cases. 
 
 
CI: Confidence Intervals; CRC: Colorectal cancer; HR: Hazard ratio.  
*Adjusted for: sex (male/female), adjuvant chemotherapy use (yes/no), age (<50, 50-<60, 60-<70, 70-<80, ≥80 years), year of diagnosis (2004-2008), stage 
(II/III), family history of colorectal cancer (yes/no/unknown), MSI status (non MSI-high/MSI-high/unknown), extramural venous invasion (no/yes/unknown), 
and ECOG status (0-1/2/3-4/unknown), differentiation (well-moderate/poor) and (for all-cause mortality analysis only) Charlson co-morbidity score (0-7). 
  Colorectal cancer-specific mortality All cause mortality 
Morphological feature Alive  
n=239 (%) 
CRC death 
n=144 (%) 
Unadjusted HR 
(95%CI) 
Adjusted HR* 
(95%CI) 
Death 
n=206 (%) 
Unadjusted HR 
(95%CI) 
Adjusted HR* 
(95%CI) 
Peritumoral lymphoid inflammation 
  0 
  1/2 
 
22    (9.2) 
217 (90.8) 
 
27   (18.8) 
117 (81.3) 
 
1.00 
0.49 (0.32-0.75) 
 
1.00 
0.48 (0.31-0.76) 
 
31    (15.1) 
175 (84.9) 
 
1.00 
0.63 (0.43-0.92) 
 
1.00 
0.63 (0.42-0.95) 
Crohn’s disease-like reaction 
  0 
  1/2  
 
67   (28.0) 
172 (72.0) 
 
65 (45.1) 
79 (54.9) 
 
1.00 
0.54 (0.39-0.74) 
 
1.00 
0.60 (0.42-0.84) 
 
86    (41.8) 
120 (58.2) 
 
1.00 
0.61 (0.47-0.81) 
 
1.00 
0.64 (0.48-0.86) 
Tumor stromal % (focal)   
  <50% 
  >50% 
 
191 (79.9) 
48   (20.1) 
 
108 (75.0) 
36   (25.0) 
 
1.00 
1.28 (0.88-1.87) 
 
1.00 
1.14 (0.75-1.72) 
 
155 (75.2) 
51   (24.8) 
 
1.00 
1.27 (0.93-1.75) 
 
1.00 
1.23 (0.87-1.73) 
Tumor stromal % (global) 
  <50% 
  >50% 
 
212 (88.7) 
27   (11.3) 
 
116 (80.6) 
28   (19.4) 
 
1.00 
1.60 (1.06-2.41) 
 
1.00 
1.45 (0.92-2.29) 
 
168 (81.6) 
38   (18.4) 
 
1.00 
1.52 (1.07-2.16) 
 
1.00 
1.49 (1.02-2.20) 
 Table 5. Combined score of fibroinflammatory morphological features and risk of colorectal cancer-specific or overall death in stage II and III colon cancer 
cases. 
 
 
 
 
 
CI: Confidence intervals; CRC: Colorectal cancer; HR: Hazard ratio. 
* Combined score based on peritumoral inflammation (1 point if score 0 or 1), Crohn’s disease-like reaction (1 point if score 0 or 1) and global tumor 
stromal percentage (1 point if >50%) to give a maximum combined fibroinflammatory index score of 3. Very few patients had a score of 3, therefore this 
was combined with a score of 2 for statistical analysis. 
**Adjusted for: sex (male/female), adjuvant chemotherapy use (yes/no), age (<50, 50-<60, 60-<70, 70-<80, ≥80 years), year of diagnosis (2004-2008), stage 
(II/III), family history of colorectal cancer (yes/no/unknown), MSI status (non MSI-high/MSI-high/unknown), extramural venous invasion (no/yes/unknown), 
ECOG status (0-1/2/3-4/unknown), differentiation (well-moderate/poor) and (for all-cause mortality analysis only) Charlson co-morbidity score (0-7). 
 
 
 
 
     CRC-specific mortality  All-cause mortality 
Combined 
fibroinflammatory  
index score* 
Alive 
n=239 (%) 
CRC death 
n=144 (%) 
Unadjusted HR 
(95%CI) 
Adjusted HR** 
(95%CI) 
Death 
n=206 (%) 
Unadjusted HR 
(95%CI) 
Adjusted HR** 
(95%CI) 
 
0 
1 
2-3 
 
150 (62.8) 
65   (27.2) 
24   (10.0) 
 
61 (42.4) 
49 (34.0) 
35 (23.6) 
 
1.00 
1.75 (1.20-2.54) 
2.65 (1.74-4.03) 
 
1.00 
1.53 (1.02-2.28) 
2.44 (1.56-3.81) 
 
97 (47.1) 
67 (32.5) 
42 (20.4) 
 
1.00 
1.52 (1.12-2.08) 
2.08 (1.45-2.99) 
 
1.00 
1.46 (1.05-2.04) 
2.00 (1.36-2.95) 
 Figure 1.  
 
 Figure 2. 
 
 Figure 3. 
 
 Figure 4. Kaplan Meier graph showing colorectal cancer-specific survival amongst Stage II and III 
colon cancer patients according to the combined fibro-inflammatory index score. 
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 Figure 5.  Risk of colorectal cancer-specific death according to morphological features in stage II and 
III colon cancer cases, stratified by microsatellite instability status. 
 
CI: Confidence intervals; HR: Hazard ratio; MSI: Microsatellite instability.  Results for peritumoral 
inflammation and Crohn’s disease-like reaction are comparing scores 1/2 v. 0 for each and results for 
tumor stromal percentage (global) are comparing >50% v. <50%. Combined score is based on 
peritumoral inflammation (1 point if score 0), Crohn’s disease-like reaction (1 point if score 0) and 
global tumor stromal percentage (1 point if >50%) to give a maximum combined fibroinflammatory 
index score of 3. Very few patients had a score of 3, therefore this was combined with a score of 2 
for statistical analysis. 
 
**Adjusted for: sex (male/female), adjuvant chemotherapy use (yes/no – except for chemotherapy 
stratified analysis), age (<50, 50-<60, 60-<70, 70-<80, ≥80 years), year of diagnosis (2004-2008), 
stage (II/III – except for stage stratified analysis), family history of colorectal cancer 
(yes/no/unknown), MSI status (non MSI-high/MSI-high/unknown – except for MSI stratified 
analysis), extramural venous invasion (no/yes/unknown), ECOG status (0-1/2/3-4/unknown) and 
differentiation (well-moderate /poor). 
 
 
Morphological feature  Adjusted HR** 
(95%CI) 
P for 
interaction 
 
Peritumoral inflammation  
  
  MSI-High  
  Non MSI-High  
 0.16 (0.04-0.57) 
0.76 (0.44-1.32) 
 
0.002 
 
Crohn’s disease-like reaction  
  
  MSI-High  
  Non MSI-High 
 0.28 (0.08-0.92) 
0.74 (0.50-1.11) 
 
0.07 
 
Tumor stromal % (global) 
  
  MSI-High  
  Non MSI-High 
 0.73 (0.09-6.06) 
1.45 (0.86-2.44) 
 
0.53 
 
Combined score 
  MSI-High 
    1 v. 0 
    2-3 v. 0 
 
 
 
 
 
3.20 (0.95-10.76) 
6.06 (1.57-27.97) 
 
 
 
 
 
   Non MSI-High 
    1 v. 0 
    2-3 v. 0 
  
1.21 (0.77-1.91) 
1.66 (0.98-2.81) 
 
 
0.01 
                                   
                                                0.1  0.3 0.5  0.7     1      1.5   2   3           6 
      
 Supplementary Table 1.  Risk of colorectal cancer-specific death according to microenvironmental 
features in stage II and III colon cancer cases, stratified by stage and adjuvant chemotherapy use. 
 
Supplementary Table 1 legend. 
CI: Confidence intervals; CRC: Colorectal cancer; HR: Hazard ratio. 
* Combined score based on peritumoral inflammation (1 point if score 0 or 1), Crohn’s disease-like 
reaction (1 point if score 0 or 1) and global tumor stromal percentage (1 point if >50%) to give a 
maximum combined fibroinflammatory index score of 3. Very few patients had a score of 3, 
therefore this was combined with a score of 2 for statistical analysis. 
**Adjusted for: Sex (male/female), adjuvant chemotherapy use (yes/no – except for chemotherapy 
stratified analysis), age (<50, 50-<60, 60-<70, 70-<80, ≥80 years), year of diagnosis (2004-2008), 
stage (II/III – except for stage stratified analysis), family history of colorectal cancer 
(yes/no/unknown), MSI status (non MSI-high/MSI-high/unknown – except for MSI stratified 
analysis), extramural venous invasion (no/yes/unknown), ECOG status (0-1/2/3-4/unknown) and 
differentiation (moderate-well/poor). 
Morphological feature Number of 
patients alive/ 
CRC deaths 
Adjusted HR** 
(95%CI) 
Number of 
patients alive/ 
CRC deaths 
Adjusted HR** 
(95%CI) 
 
P for 
interaction 
By stage  Stage II  Stage III  
Peritumoral inflammation     
  Absent/Mild  
  Moderate/Severe 
15/10 
145/55 
1.00 
0.74 (0.35-1.54) 
7/17 
72/62 
1.00 
0.41 (0.22-0.76) 
 
0.10 
Crohn’s disease-like reaction     
  Absent/Mild  
  Moderate/Severe  
42/25 
118/40 
1.00 
0.75 (0.44-1.28) 
25/40 
54/39 
1.00 
0.54 (0.33-0.89) 
 
0.61 
Tumor stromal % (global)     
  <50% 
  >50% 
147/52 
13/13 
1.00 
1.74 (0.90-3.40) 
65/73 
14/18 
1.00 
1.17 (0.60-2.29) 
 
0.15 
Combined score* 
  0 
  1 
  2-3 
 
107/30 
38/23 
15/12 
 
1.00 
1.61 (0.89-2.92) 
1.81 (0.88-3.75) 
 
43/31 
27/26 
9/22 
 
1.00 
1.55 (0.86-2.75) 
2.61 (1.38-4.94) 
 
 
 
0.62 
By adjuvant chemotherapy use No  Yes  
Peritumoral inflammation     
  Absent/Mild  
  Moderate/Severe 
16/18 
141/87 
1.00 
0.57 (0.33-0.99) 
6/9 
76/30 
1.00 
0.34 (0.14-0.81) 
 
0.58 
Crohn’s disease-like reaction     
  Absent/Mild  
  Moderate/Severe  
42/47 
115/58 
1.00 
0.62 (0.41-0.94) 
25/18 
57/21 
1.00 
0.69 (0.32-1.49) 
 
0.58 
Tumor stromal % (global)     
  <50% 
  >50% 
144/86 
13/19 
1.00 
1.52 (0.87-2.66) 
68/30 
14/9 
1.00 
1.11 (0.45-2.69) 
 
0.63 
Combined score* 
  0 
  1 
  2-3 
 
103/48 
39/32 
15/25 
 
1.00 
1.28 (0.79-2.09) 
2.23 (1.32-3.77) 
 
47/13 
26/17 
9/9 
 
1.00 
2.01 (0.83-4.84) 
2.70 (0.99-7.37) 
 
 
 
0.61 
